Skip to main content

Advertisement

SpringerLink
Log in

Poor Response to Pegylated Interferon and Ribavirin in Older Women Infected with Hepatitis C Virus of Genotype 1b in High Viral Loads

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Background Response to treatment in patients with chronic hepatitis C, with reference to age and gender, has not been examined fully. Aim The influence of gender and age on treatment with pegylated interferon (PEG-IFN) and ribavirin was evaluated in a retrospective study. Methods PEG-IFN and ribavirin were given for 48 weeks to 179 men and 121 women infected with hepatitis C virus (HCV) of genotype 1b in high viral loads (>100 kIU/ml). Results Sustained virological response at 24 weeks after treatment was poorer in women than men who were aged ≥50 years (22% vs 53%, P < 0.001). Among the patients aged ≥50 years who had received ≥80% of the doses of PEG-IFN, ribavirin, or both, women responded less often than men (26% vs 64%, P < 0.001; 33% vs 61%, P = 0.022; and 32% vs 63%, P = 0.016; respectively). In multivariate analysis, male gender, retention of indocyanine green, ribavirin dose and compliance with therapy increased sustained virological response. Conclusions Response to combined PEG-IFN and ribavirin is poorer in female than male patients with hepatitis C who are aged ≥50 years, irrespective of compliance with treatment. Low estrogen levels in older women could be responsible for their impaired response to PEG-IFN and ribavirin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Cohen J. The scientific challenge of hepatitis C. Science. 1999;285:26–30. doi:10.1126/science.285.5424.26.

    Article  PubMed  CAS  Google Scholar 

  2. Alberti A, Chemello L, Benvegnu L. Natural history of hepatitis C. J Hepatol. 1999;31:S17–S24. doi:10.1016/S0168-8278(99)80369-9.

    Article  Google Scholar 

  3. Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis. 2000;20:17–35. doi:10.1055/s-2000-9505.

    Article  PubMed  CAS  Google Scholar 

  4. Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36:S35–S46. doi:10.1002/hep.1840360706.

    Article  PubMed  Google Scholar 

  5. Feray C, Gigou M, Samuel D, et al. Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation. Gastroenterology. 1995;108:1088–1096. doi:10.1016/0016-5085(95)90207-4.

    Article  PubMed  CAS  Google Scholar 

  6. Garcia-Samaniego J, Soriano V, Castilla J, et al. Influence of hepatitis C virus genotypes and HIV infection on histological severity of chronic hepatitis C. Am J Gastroenterol. 1997;92:1130–1134.

    PubMed  CAS  Google Scholar 

  7. Pageaux GP, Ducos J, Mondain AM, et al. Hepatitis C virus genotypes and quantitation of serum hepatitis C virus RNA in liver transplant recipients: relationship with severity of histological recurrence and implications in the pathogenesis of HCV infection. Liver Transpl Surg. 1997;3:501–505. doi:10.1002/lt.500030504.

    Article  PubMed  CAS  Google Scholar 

  8. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med. 1999;340:1228–1233. doi:10.1056/NEJM199904223401602.

    Article  PubMed  CAS  Google Scholar 

  9. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet. 1997;349:825–832. doi:10.1016/S0140-6736(96)07642-8.

    Article  PubMed  CAS  Google Scholar 

  10. Vogt M, Lang T, Frosner G, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med. 1999;341:866–870. doi:10.1056/NEJM199909163411202.

    Article  PubMed  CAS  Google Scholar 

  11. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med. 1998;339:1485–1492. doi:10.1056/NEJM199811193392101.

    Article  PubMed  CAS  Google Scholar 

  12. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982. doi:10.1056/NEJMoa020047.

    Article  PubMed  CAS  Google Scholar 

  13. Hung CH, Lee CM, Lu SN, et al. Anemia associated with antiviral therapy in chronic hepatitis C: incidence, risk factors, and impact on treatment response. Liver Int. 2006;26:1079–1086. doi:10.1111/j.1478-3231.2006.01354.x.

    Article  PubMed  CAS  Google Scholar 

  14. Akuta N, Suzuki F, Kawamura Y, et al. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. J Med Virol. 2007;79:1686–1695. doi:10.1002/jmv.20979.

    Article  PubMed  CAS  Google Scholar 

  15. Sezaki H, Suzuki F, Kawamura Y, et al. Evaluation of long-term biochemical responses to combination therapy of interferon plus ribavirin in those infected with hepatitis C virus genotype 1b and high baseline viral load. Hepatol Res. 2007;37:787–792. doi:10.1111/j.1872-034X.2007.00132.x.

    Article  PubMed  CAS  Google Scholar 

  16. Conjeevaram HS, Fried MW, Jeffers LJ, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology. 2006;131:470–477. doi:10.1053/j.gastro.2006.06.008.

    Article  PubMed  CAS  Google Scholar 

  17. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet. 1998;352:1426–1432. doi:10.1016/S0140-6736(98)07124-4.

    Article  PubMed  CAS  Google Scholar 

  18. Tsubota A, Chayama K, Ikeda K, et al. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology. 1994;19:1088–1094.

    Article  PubMed  CAS  Google Scholar 

  19. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346–355.

    PubMed  CAS  Google Scholar 

  20. Hui CK, Yuen MF, Sablon E, Chan AO, Wong BC, Lai CL. Interferon and ribavirin therapy for chronic hepatitis C virus genotype 6: a comparison with genotype 1. J Infect Dis. 2003;187:1071–1074. doi:10.1086/368217.

    Article  PubMed  CAS  Google Scholar 

  21. Legrand-Abravanel F, Nicot F, Boulestin A, et al. Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection. J Med Virol. 2005;77:66–69. doi:10.1002/jmv.20414.

    Article  PubMed  CAS  Google Scholar 

  22. Yuen MF, Lai CL. Response to combined interferon and ribavirin is better in patients infected with hepatitis C virus genotype 6 than genotype 1 in Hong Kong. Intervirology. 2006;49:96–98. doi:10.1159/000087270.

    Article  PubMed  CAS  Google Scholar 

  23. Kumada T, Toyoda H, Honda T, et al. Treatment of chronic hepatitis C with interferon alone or combined with ribavirin in Japan. Intervirology. 2006;49:112–118. doi:10.1159/000087273.

    Article  PubMed  CAS  Google Scholar 

  24. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med. 2000;132:296–305.

    PubMed  CAS  Google Scholar 

  25. Trepo C. Genotype and viral load as prognostic indicators in the treatment of hepatitis C. J Viral Hepat. 2000;7:250–257. doi:10.1046/j.1365-2893.2000.00233.x.

    Article  PubMed  CAS  Google Scholar 

  26. Wali M, Harrison RF, Gow PJ, Mutimer D. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut. 2002;51:248–252. doi:10.1136/gut.51.2.248.

    Article  PubMed  CAS  Google Scholar 

  27. Takaki S, Tsubota A, Hosaka T, et al. Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C. J Gastroenterol. 2004;39:668–673. doi:10.1007/s00535-003-1363-9.

    Article  PubMed  CAS  Google Scholar 

  28. Hayashi J, Kishihara Y, Ueno K, et al. Age-related response to interferon alfa treatment in women vs men with chronic hepatitis C virus infection. Arch Intern Med. 1998;158:177–181. doi:10.1001/archinte.158.2.177.

    Article  PubMed  CAS  Google Scholar 

  29. Khosla S, Melton LJ 3rd, Atkinson EJ, O’Fallon WM, Klee GG, Riggs BL. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab. 1998;83:2266–2274. doi:10.1210/jc.83.7.2266.

    Article  PubMed  CAS  Google Scholar 

  30. Yasuda M, Shimizu I, Shiba M, Ito S. Suppressive effects of estradiol on dimethylnitrosamine-induced fibrosis of the liver in rats. Hepatology. 1999;29:719–727. doi:10.1002/hep.510290307.

    Article  PubMed  CAS  Google Scholar 

  31. Rossini GP, Baldini GM, Villa E, Manenti F. Characterization of estrogen receptor from human liver. Gastroenterology. 1989;96:1102–1109.

    PubMed  CAS  Google Scholar 

  32. Shiba M, Shimizu I, Yasuda M, Ii K, Ito S. Expression of type I and type III collagens during the course of dimethylnitrosamine-induced hepatic fibrosis in rats. Liver. 1998;18:196–204.

    PubMed  CAS  Google Scholar 

  33. Di Martino V, Lebray P, Myers RP, et al. Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure. Hepatology. 2004;40:1426–1433. doi:10.1002/hep.20463.

    Article  PubMed  CAS  Google Scholar 

  34. Sartori M, Andorno S, Rigamonti C, Grossini E, Nicosia G, Boldorini R. Chronic hepatitis C is mild in menstruating women. J Gastroenterol Hepatol. 2000;15:1411–1417. doi:10.1046/j.1440-1746.2000.02368.x.

    Article  PubMed  CAS  Google Scholar 

  35. Latt NC, Spencer JD, Beeby PJ, et al. Hepatitis C in injecting drug-using women during and after pregnancy. J Gastroenterol Hepatol. 2000;15:175–181. doi:10.1046/j.1440-1746.2000.02060.x.

    Article  PubMed  CAS  Google Scholar 

  36. Levine RA, Sanderson SO, Ploutz-Snyder R, et al. Assessment of fibrosis progression in untreated Irish women with chronic hepatitis C contracted from immunoglobulin anti-D. Clin Gastroenterol Hepatol. 2006;4:1271–1277. doi:10.1016/j.cgh.2006.05.028.

    Article  PubMed  Google Scholar 

  37. Wiese M, Berr F, Lafrenz M, Porst H, Oesen U. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: a 20-year multicenter study. Hepatology. 2000;32:91–96. doi:10.1053/jhep.2000.8169.

    Article  PubMed  CAS  Google Scholar 

  38. Braunstein GD. Gynecomastia. N Engl J Med. 1993;328:490–495. doi:10.1056/NEJM199302183280708.

    Article  PubMed  CAS  Google Scholar 

  39. Carey EJ, Balan V, Kremers WK, Hay JE. Osteopenia and osteoporosis in patients with end-stage liver disease caused by hepatitis C and alcoholic liver disease: not just a cholestatic problem. Liver Transpl. 2003;9:1166–1173. doi:10.1053/jlts.2003.50242.

    Article  PubMed  Google Scholar 

Download references

Acknowledgment

This study was supported, in part, by grants from the Ministry of Health, Labour and Welfare of Japan.

Author information

Authors and Affiliations

  1. Department of Hepatology, Toranomon Hospital, Minato-ku, Tokyo, 105-8470, Japan

    Hitomi Sezaki, Fumitaka Suzuki, Yusuke Kawamura, Hiromi Yatsuji, Tetsuya Hosaka, Norio Akuta, Masahiro Kobayashi, Yoshiyuki Suzuki, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda & Hiromitsu Kumada

  2. Miyakawa Memorial Research Foundation, Tokyo, Japan

    Yuzo Miyakawa

Authors
  1. Hitomi Sezaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fumitaka Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yusuke Kawamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hiromi Yatsuji
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tetsuya Hosaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Norio Akuta
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Masahiro Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yoshiyuki Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Satoshi Saitoh
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yasuji Arase
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Kenji Ikeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Yuzo Miyakawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Hiromitsu Kumada
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hitomi Sezaki.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sezaki, H., Suzuki, F., Kawamura, Y. et al. Poor Response to Pegylated Interferon and Ribavirin in Older Women Infected with Hepatitis C Virus of Genotype 1b in High Viral Loads. Dig Dis Sci 54, 1317–1324 (2009). https://doi.org/10.1007/s10620-008-0500-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-008-0500-y

Keywords

Search

Navigation